Truxima is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.

INN:

Subtype:

Diffuse Large B-Cell Lymphoma (DLBCL)

License:

EMA

Class:

CD20 monoclonal antibody

Newly Diagnosed

SmPC: https://www.medicines.org.uk/emc/medicine/33201

 

1. Approved Labelling

Truxima is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.

2. Treatment Regimen

Truxima should be used in combination with CHOP chemotherapy. The recommended dosage is 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles after intravenous infusion of the glucocorticoid component of CHOP. Safety and efficacy of Truxima have not been established in combination with other chemotherapies in diffuse large B cell non-Hodgkin's lymphoma.

3. AE/Warnings

Please see section 4.4 of the SmPC

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.